PubMed
Hexarelin, a synthetic growth hormone-releasing peptide, vs GHRH in GH-deficient adults
Ghigo E, Arvat E, Muccioli G, et al. Eur J Endocrinol. 1996
Compare
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 48% · Mixed 44% · Unfavorable overall 8%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 100–200 mcg · Most common: 100–200 mcg
Reports span 25–600 mcg
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 58% said they felt similar to their last entry, 28% more positive, and 18% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 32 days · Based on 269 repeat reporters
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 44% · Mixed 46% · Unfavorable overall 10%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 0.4–0.6 mg · Most common: 0.4–0.6 mg
Reports span 0.05–3 mg
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 54% said they felt similar to their last entry, 42% more positive, and 14% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 22 days · Based on 381 repeat reporters
Published sources linked on the Hexarelin and Semax wiki pages.
PubMed
Ghigo E, Arvat E, Muccioli G, et al. Eur J Endocrinol. 1996
PubMed
Bisi G, Podio V, Valetto MR, et al. Growth Horm IGF Res. 2001
ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
PubMed
Kolovou GD, Kolovou V, Mavrogeni S. BioMed research international. 2014
PubMed
Mao Y, Tokudome T, Kishimoto I. Journal of geriatric cardiology : JGC. 2014
PubMed
Dmitrieva VG, Povarova OV, Skvortsova VI, et al. Mol Genet Genomics. 2013
PubMed
Ashmarin IP, Nezavibatko VN, Levitskaya NG, et al. Neurosci Res. 2006
PubMed
Dolotov OV, Karpenko EA, Inozemtseva LS, et al. J Neurochem. 2008
ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
PubMed
Giri S, Chandra P. Neuropeptides. 2025
PubMed
Gusev EI, Martynov MY, Kostenko EV, et al. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2018